Dabur misses estimates, profit drops 8% to Rs 320 crore

Dabur India on Wednesday reported an 8.4% year-on-year decline in net profit for the January–March quarter, at Rs 320.13 crore. The figure fell short of Bloomberg’s consensus estimate of Rs 324 crore, as tepid urban demand, particularly in general trade channels, continued to weigh on performance.

Revenue from operations for the quarter rose a marginal 0.6% year-on-year to Rs 2,830.14 crore, below Bloomberg’s projection of Rs 2,846 crore. The company’s Ebitda also missed expectations, registering at Rs 426.8 crore against a projected Rs 438 crore.

Dabur’s underperformance in urban general trade was a key drag, despite double-digit growth across modern trade, e-commerce, and rural channels. CEO Mohit Malhotra acknowledged the pressure in urban consumption and laid out a refreshed seven-point strategic plan aimed at delivering a double-digit compound annual growth rate (CAGR) by FY28.

Central to this plan is a sharpened focus on Dabur’s core portfolio, which includes brands like Dabur Red, Real, Chyawanprash, Honey, Hajmola, Odonil, and Vatika, accounting for roughly 70% of total business. The company intends to step up investments in these high-conviction brands to gain market share, while also pruning underperforming categories such as vedic teas and diapers to reallocate capital more efficiently.

In addition, Dabur plans to drive premiumisation across its portfolio to bolster margins. It has identified growth segments such as hair serums, conditioners, and health gummies, and is preparing to launch zero-sugar, preservative-free beverages as part of this strategy. Malhotra said this move aligns with shifting consumer preferences and will help Dabur pivot toward higher-value offerings.

To further address urban trade inefficiencies, Dabur aims to consolidate its network of stockists to optimise return on investment and reduce cost-to-serve in metro markets. It also plans to strengthen its presence in high-growth channels, including e-commerce, quick commerce, and modern trade, which have shown sustained momentum.

Dabur India plunges 7.5%: 3 big concerns for investors

The company is also eyeing inorganic growth through mergers and acquisitions in segments like new-age healthcare, wellness foods, and premium personal care. Malhotra described this approach as part of building a future-fit portfolio that aligns with evolving consumer demands.

Looking ahead, Dabur expects sequential recovery from the April–June quarter and is targeting high single-digit to low double-digit revenue growth in FY26. For the full year FY25, net profit declined to Rs 1,740.42 crore from Rs 1,811.31 crore in FY24. The board has recommended a final dividend of Rs 5.25 per equity share for the fiscal.

Related Posts

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

New Delhi: AstraZeneca’s India-arm has partnered with National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging geographies in a bid to extend…

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction